HOME    |    SITEMAP    |    CONTACT    |    

Share  | 
Partnering

Current Collaborations

In August 2012, Mersana announced a first of its kind alliance with Adimab which will enable next-generation ADC discovery and development for top 25 pharmaceutical companies. Through this collaboration, Adimab and Mersana will offer potential pharmaceutical partners integrated access to Adimab's world-class antibodies, which have been optimized for use in ADCs, together with Mersana's Fleximer polymer and broad array of customizable linkers for attaching diverse, potent payloads.  

In March 2012, Mersana announced a collaboration, worth potentially more than $270 million, with Endo Pharmaceuticals to develop next-generation antibody-drug conjugates (ADCs) against a single cancer target using Mersana's proprietary conjugation technology. Under the terms of the agreement, Endo will pay an upfront fee to Mersana, who is responsible for conducting research and creating ADCs that are conjugates of the Company's diverse, highly potent cytotoxic payloads, its Fleximer polymer and custom linkers, and Endo's novel antibodies. Endo is responsible for product development, manufacturing and commercialization of any Fleximer-ADC products. Mersana and Endo may mutually agree to pursue two additional targets over the next two years. Mersana is eligible to receive progress-dependent milestones as well as royalties on worldwide net sales of any resulting ADC products.

In April 2010, Mersana announced a $334 million collaboration with Teva Pharmaceuticals for the development and commercialization of XMT-1107 in all indications. Under the terms of the agreement, Teva received an exclusive license to XMT-1107 worldwide, excluding Japan, for which Mersana elected to retain rights. In return, Mersana received $9 million in upfront payments and is eligible to receive development, regulatory and commercial milestones, plus up to double-digit royalties on sales on any approved products from the XMT-1107 program that are developed and commercialized by Teva. In addition, Teva is covering development costs for XMT-1107. A Phase 1 trial in patients with refractory, advanced solid tumors has been completed.